Products

Lenakast 10mg Capsule – Product Description Lenakast 10mg Capsule is a prescription medicine commonly used in the management of allergic conditions, depending on its active ingredient and prescribed indication. It may help relieve symptoms such as sneezing, runny or blocked nose, itching, and watery eyes. Key Benefits: Helps manage allergy-related symptoms May reduce sneezing and nasal irritation Helps relieve itching and watery eyes Can support better comfort during allergic episodes Important: Use Lenakast 10mg Capsule only as directed by a qualified healthcare professional. The exact uses, dosage, precautions, and side effects depend on the medicine's active ingredient and the patient's condition. Avoid self-medication.

Description Lenangio 10mg Capsule: Advanced Immunomodulatory Therapy for Multiple Myeloma and Myelodysplastic Syndromes Extensive Product Profile: In-Depth Insights on Lenangio 10mg Capsules Lenangio 10mg Capsule, manufactured under strict global GMP compliance standards within India, is a highly effective mid-range oral antineoplastic and immunomodulatory treatment. Each capsule contains precisely Lenalidomide ($10text{ mg}$) as its active pharmaceutical ingredient. Lenalidomide is a potent analogue of thalidomide belonging to the chemical class of isoindolones. It is designed to selectively manipulate cellular environments, alter cytokine release, and stimulate defense cells to disrupt blood-based cancers at their core. 1. Clinical Indications & Target Therapeutic Applications Multiple Myeloma (MM): Used in combination with dexamethasone or as a standalone maintenance therapy following autologous stem cell transplantation (ASCT) for patients with newly diagnosed or relapsed/refractory multiple myeloma. The $10text{ mg}$ strength is highly utilized for strategic dose maintenance or during scheduled step-down titration cycles to control drug toxicity. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a specific cytogenetic abnormality—the deletion 5q (del 5q) chromosomal mutation, with or without additional cytogenetic abnormalities. Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which must have included bortezomib. 2. Comprehensive Mechanism of Action (MOA) Cereblon E3 Ubiquitin Ligase Binding: Lenalidomide binds directly to cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex. This binding selectively alters the substrate specificity of the ligase, targeting two essential lymphoid transcription factors—IKZF1 (Ikaros) and IKZF3 (Aiolos)—for rapid cellular degradation. Direct Tumor Suppression & Apoptosis: The destruction of Ikaros and Aiolos causes a down-regulation of crucial survival factors in B-cell malignancies, leading to immediate cell cycle arrest and programmed cell death (apoptosis) in malignant plasma cells. 3. Storage, Stability, and Handling Protocols Environmental Matrix: Store Lenangio 10mg Capsules in their original moisture-resistant container or blister packaging at controlled room temperature, strictly below 30°C (86°F). Protect the inventory from high ambient steam, humidity, heat, and direct exposure to light. Administration Matrix: Capsules must be swallowed completely whole with a glass of water, once daily at the same time, either with or without food. Do not crush, chew, open, or break the capsule shell, as direct contact with the internal powder poses handling risks and alters designated absorption rates. Potential Side Effects of Lenangio 10mg Severe Myelosuppression: Significant reductions in blood cell counts, leading to severe neutropenia (low white cells increasing susceptibility to infections), thrombocytopenia (low platelets increasing bruising or bleeding hazards), and anemia (causing extreme fatigue and weakness). Regular Complete Blood Counts (CBC) are required before and during treatment. Venous and Arterial Thromboembolism: Patients treated with Lenalidomide face a significantly increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke. Prophylactic antithrombotic therapy is highly recommended for most patients.

Description Lenangio 10mg Capsule: Advanced Immunomodulatory Therapy for Multiple Myeloma and Myelodysplastic Syndromes Extensive Product Profile: In-Depth Insights on Lenangio 10mg Capsules Lenangio 10mg Capsule, manufactured under strict global GMP compliance standards within India, is a highly effective mid-range oral antineoplastic and immunomodulatory treatment. Each capsule contains precisely Lenalidomide ($10text{ mg}$) as its active pharmaceutical ingredient. Lenalidomide is a potent analogue of thalidomide belonging to the chemical class of isoindolones. It is designed to selectively manipulate cellular environments, alter cytokine release, and stimulate defense cells to disrupt blood-based cancers at their core. 1. Clinical Indications & Target Therapeutic Applications Multiple Myeloma (MM): Used in combination with dexamethasone or as a standalone maintenance therapy following autologous stem cell transplantation (ASCT) for patients with newly diagnosed or relapsed/refractory multiple myeloma. The $10text{ mg}$ strength is highly utilized for strategic dose maintenance or during scheduled step-down titration cycles to control drug toxicity. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a specific cytogenetic abnormality—the deletion 5q (del 5q) chromosomal mutation, with or without additional cytogenetic abnormalities. Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which must have included bortezomib. 2. Comprehensive Mechanism of Action (MOA) Cereblon E3 Ubiquitin Ligase Binding: Lenalidomide binds directly to cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex. This binding selectively alters the substrate specificity of the ligase, targeting two essential lymphoid transcription factors—IKZF1 (Ikaros) and IKZF3 (Aiolos)—for rapid cellular degradation. Direct Tumor Suppression & Apoptosis: The destruction of Ikaros and Aiolos causes a down-regulation of crucial survival factors in B-cell malignancies, leading to immediate cell cycle arrest and programmed cell death (apoptosis) in malignant plasma cells. 3. Storage, Stability, and Handling Protocols Environmental Matrix: Store Lenangio 10mg Capsules in their original moisture-resistant container or blister packaging at controlled room temperature, strictly below 30°C (86°F). Protect the inventory from high ambient steam, humidity, heat, and direct exposure to light.

Description Lendomy 10mg Capsule: Advanced Immunomodulatory Therapy for Multiple Myeloma and Myelodysplastic Syndromes Extensive Product Profile: In-Depth Insights on Lendomy 10mg Capsules Lendomy 10mg Capsule, manufactured under strict global compliance systems within India (by Mylan/Viatris Pharmaceuticals Pvt. Ltd.), is a highly effective mid-range oral antineoplastic and immunomodulatory treatment. Each capsule contains precisely Lenalidomide ($10text{ mg}$) as its active pharmaceutical ingredient. Lenalidomide is a potent analogue of thalidomide belonging to the chemical class of isoindolones. It is designed to selectively manipulate cellular environments, alter cytokine release, and stimulate defense cells to disrupt blood-based cancers at their core. 1. Clinical Indications & Target Therapeutic Applications Multiple Myeloma (MM): Used in combination with dexamethasone or as a standalone maintenance therapy following autologous stem cell transplantation (ASCT) for patients with newly diagnosed or relapsed/refractory multiple myeloma. The $10text{ mg}$ strength is highly utilized for strategic dose maintenance or during scheduled step-down titration cycles to control drug toxicity. Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which must have included bortezomib. Follicular Lymphoma (FL) & Marginal Zone Lymphoma (MZL): Utilized in combination with rituximab for previously treated adults with follicular or marginal zone lymphomas to control slow-progressing B-cell cancers. 2. Comprehensive Mechanism of Action (MOA) Cereblon E3 Ubiquitin Ligase Binding: Lenalidomide binds directly to cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex. This binding selectively alters the substrate specificity of the ligase, targeting two essential lymphoid transcription factors—IKZF1 (Ikaros) and IKZF3 (Aiolos)—for rapid cellular degradation. Immune System Modulation: It heavily boosts the body's natural defenses by stimulating T-cells and Natural Killer (NK) cells, increasing their capacity to recognize, attack, and clear out abnormal cancer cells roaming the bone marrow. 3. Storage, Stability, and Handling Protocols Environmental Matrix: Store Lendomy 10mg Capsules in their original moisture-resistant container or blister packaging at controlled room temperature, strictly below 30°C (86°F). Protect the inventory from high ambient steam, humidity, heat, and direct exposure to light. Administration Matrix: Capsules must be swallowed completely whole with a glass of water, once daily at the same time, either with or without food. Do not crush, chew, open, or break the capsule shell, as direct contact with the internal powder poses handling risks and alters designated absorption rates. Potential Side Effects of Lendomy 10mg Severe Myelosuppression: Significant reductions in blood cell counts, leading to severe neutropenia (low white cells increasing susceptibility to infections), thrombocytopenia (low platelets increasing bruising or bleeding hazards), and anemia (causing extreme fatigue and weakness). Regular Complete Blood Counts (CBC) are required before and during treatment. Venous and Arterial Thromboembolism: Patients treated with Lenalidomide face a significantly increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke. Prophylactic antithrombotic therapy is highly recommended for most patients. Export Documentation & Global Trade Compliance Certificate of Analysis (COA): Providing verifiable batch testing confirming the precise $10text{ mg}$ Lenalidomide strength, active capsule dissolution profiles, and chemical purity indices.

Description Tukavo 150mg Tablet: Advanced Targeted Tyrosine Kinase Inhibitor for HER2-Positive Metastatic Cancer Care Extensive Product Profile: In-Depth Insights on Tukavo 150mg Tablets Tukavo 150mg Tablet, manufactured under strict global compliance systems within India by Zydus Lifesciences Ltd. (Oncology Division), is a breakthrough oral targeted therapy. Each film-coated tablet contains precisely Tucatinib ($150text{ mg}$) as its active pharmaceutical ingredient. Unlike non-selective treatments, tucatinib is a highly selective tyrosine kinase inhibitor (TKI) engineered to intercept and block the signaling pathways that fuel Human Epidermal Growth Factor Receptor 2 (HER2) positive malignancies, offering an exceptional therapeutic option for difficult-to-treat and recurrent cases. 1. Clinical Indications & Target Therapeutic Applications Advanced or Metastatic HER2-Positive Breast Cancer: Indicated in combination with trastuzumab and capecitabine for adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer. This includes patients who have already progressed on one or more prior anti-HER2-based regimens. Efficacy in Brain Metastases: A distinguishing clinical advantage of Tukavo is its structural ability to cross the blood-brain barrier. It demonstrates high therapeutic efficacy in controlling and delaying progression in breast cancer patients whose disease has successfully metastasized to the brain—a population that traditionally faces limited systemic options. 2. Comprehensive Mechanism of Action (MOA) Highly Selective HER2 Kinase Inhibition: Tucatinib binds directly and reversibly to the intracellular kinase domain of the HER2 receptor. Crucially, it exhibits over 1,000-fold greater selectivity for HER2 compared to EGFR (Epidermal Growth Factor Receptor). This minimal interaction with EGFR significantly reduces systemic toxicities like severe skin rashes and severe diarrhea commonly caused by older generation, non-selective TKIs. Downstream Signaling Shutdown: By binding to the HER2 receptor, Tukavo blocks receptor autophosphorylation and completely shuts down downstream signaling pathways, specifically the MAPK and AKT pathways. These pathways are responsible for cellular proliferation, growth, and replication. 3. Storage, Stability, and Handling Protocols Environmental Matrix: Store Tukavo 150mg Tablets in their original moisture-sealed manufacturer bottle at controlled room temperature, strictly below 25°C (77°F). Keep the container firmly closed to safeguard the tablets from high ambient steam, humidity, heat, and direct light exposure. Do not transfer tablets into alternative daily pill minders. Administration Matrix: The standard therapeutic dosage is typically 300 mg (two 150 mg tablets) taken orally twice daily, approximately 12 hours apart, with or without food. Tablets must be swallowed completely whole with water. Do not crush, chew, split, or break the tablets, as this can compromise the precise film coating and affect designed absorption kinetics. Potential Side Effects of Tukavo 150mg Hepatotoxicity: Can cause significant elevations in serum transaminases (ALT and AST) and bilirubin, indicating liver stress. Liver function tests (LFTs) must be performed at baseline and monitored every 3 weeks during therapy. Severe Diarrhea: Although less toxic to EGFR than other options, diarrhea remains a very common side effect. It can become severe, leading to dehydration and electrolyte imbalances. Anti-diarrheal interventions (such as loperamide) should be initiated at the first sign of soft stools. Export Documentation & Global Trade Compliance Certificate of Analysis (COA): Providing verifiable batch testing confirming the precise $150text{ mg}$ Tucatinib strength, active dissolution profiles, and chemical purity indices. Certificate of Origin (COO): Authenticating true manufacturing provenance within registered Indian oncology production lines. Customs-Compliant Manifesting: Precision shipping manifests, clean packing lists, and commercial invoicing marked with correct global harmonized system (HS) codes for seamless clearance. PRESCRIPTION MEDICINE IS YES Disclaimer: This structural product review is prepared strictly for international business-to-business (B2B) trade procurement, wholesale distribution networks, and digital optimization indexing. Tukavo 150mg Tablet (Tucatinib) is a high-potency, restricted prescription oncology medication. It must be prescribed and managed exclusively by qualified oncologists in a specialized clinical setting.

Description Olpaza 150mg Tablet: Advanced Targeted PARP Inhibitor for BRCA-Mutated and Advanced Oncology Care Extensive Product Profile: In-Depth Insights on Olpaza 150mg Tablets Olpaza 150mg Tablet, manufactured under strict global compliance systems within India by Intas Pharmaceuticals Ltd., is a breakthrough oral targeted antineoplastic therapy. Each film-coated tablet contains precisely Olaparib ($150text{ mg}$) as its active pharmaceutical ingredient. Olaparib is a first-in-class, highly advanced PARP (Poly ADP-ribose Polymerase) inhibitor designed to exploit specific genetic vulnerabilities within tumor cells, providing a targeted mechanism that spares many healthy tissues while eliminating cancerous growths. 1. Clinical Indications & Target Therapeutic Applications Advanced Ovarian Cancer: Utilized as a vital maintenance monotherapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line or recurrent platinum-based chemotherapy. gBRCAm HER2-Negative Breast Cancer: Indicated for patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. 2. Comprehensive Mechanism of Action (MOA) PARP Enzyme Inhibition: Olpaza binds directly to and inhibits the PARP enzymes (PARP-1, PARP-2, and PARP-3). PARP proteins are crucial for repairing single-strand DNA breaks via the Base Excision Repair pathway. PARP Trapping: Beyond simple inhibition, the presence of Olaparib traps the PARP enzymes on the damaged DNA strands, stabilizing the complex. When the cell attempts to replicate, these trapped complexes cause the single-strand breaks to collapse into highly lethal double-strand DNA breaks. 3. Storage, Stability, and Handling Protocols Environmental Matrix: Store Olpaza 150mg Tablets in their original moisture-sealed manufacturer blister packaging or bottle at a controlled room temperature between 10°C to 30°C (50°F to 86°F). Protect the inventory from high ambient steam, humidity, heat, and direct light exposure. Administration Matrix: The standard therapeutic dosage is typically 300 mg (two 150 mg tablets) taken orally twice daily (morning and evening) with or without food. Tablets must be swallowed completely whole with a glass of water. Do not crush, chew, open, split, or dissolve the tablets, as this alters the designated absorption rates and drug delivery performance. Potential Side Effects of Olpaza 150mg Hematological Toxicity (Myelosuppression): Frequently causes notable decreases in blood cell counts, resulting in severe anemia (low red blood cells), neutropenia (low white blood cells making patients vulnerable to infections), and thrombocytopenia (low platelets increasing bruising risks). Regular Complete Blood Counts (CBC) are required monthly. Gastrointestinal Distress: Very common side effects include persistent nausea, vomiting, diarrhea, constipation, dyspepsia (indigestion), a notable loss of appetite, and altered taste sensations (dysgeusia). Export Documentation & Global Trade Compliance Certificate of Analysis (COA): Providing verifiable batch testing confirming the precise $150text{ mg}$ Olaparib strength, active dissolution profiles, and chemical purity indices. Certificate of Origin (COO): Authenticating true manufacturing provenance within registered Indian oncology production lines.

Description Lenid 10mg Capsule: Advanced Immunomodulatory Therapy for Multiple Myeloma and Myelodysplastic Syndromes Extensive Product Profile: In-Depth Insights on Lenid 10mg Capsules Lenid 10mg Capsule, manufactured under strict global compliance systems within India, is a highly effective, mid-range oral antineoplastic and immunomodulatory treatment. Each capsule contains precisely Lenalidomide ($10text{ mg}$) as its active pharmaceutical ingredient. Lenalidomide is a potent analogue of thalidomide belonging to the chemical class of isoindolones. It is designed to selectively manipulate cellular environments, alter cytokine release, and stimulate defense cells to disrupt blood-based cancers at their core. 1. Clinical Indications & Target Therapeutic Applications Multiple Myeloma (MM): Used in combination with dexamethasone or as a standalone maintenance therapy following autologous stem cell transplantation (ASCT) for patients with newly diagnosed or relapsed/refractory multiple myeloma. The $10text{ mg}$ strength is highly utilized for strategic dose maintenance or during scheduled step-down titration cycles to control drug toxicity. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a specific cytogenetic abnormality—the deletion 5q (del 5q) chromosomal mutation, with or without additional cytogenetic abnormalities. 2. Comprehensive Mechanism of Action (MOA) Cereblon E3 Ubiquitin Ligase Binding: Lenalidomide binds directly to cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex. This binding selectively alters the substrate specificity of the ligase, targeting two essential lymphoid transcription factors—IKZF1 (Ikaros) and IKZF3 (Aiolos)—for rapid cellular degradation. Direct Tumor Suppression & Apoptosis: The destruction of Ikaros and Aiolos causes a down-regulation of crucial survival factors in B-cell malignancies, leading to immediate cell cycle arrest and programmed cell death (apoptosis) in malignant plasma cells. 3. Storage, Stability, and Handling Protocols Environmental Matrix: Store Lenid 10mg Capsules in their original moisture-resistant container or blister packaging at controlled room temperature, strictly below 30°C (86°F). Protect the inventory from high ambient steam, humidity, heat, and direct exposure to light. Administration Matrix: Capsules must be swallowed completely whole with a glass of water, once daily at the same time, either with or without food. Do not crush, chew, open, or break the capsule shell, as direct contact with the internal powder poses handling risks and alters designated absorption rates. Potential Side Effects of Lenid 10mg Severe Myelosuppression: Significant reductions in blood cell counts, leading to severe neutropenia (low white cells increasing susceptibility to infections), thrombocytopenia (low platelets increasing bruising or bleeding hazards), and anemia (causing extreme fatigue and weakness). Regular Complete Blood Counts (CBC) are required before and during treatment. Venous and Arterial Thromboembolism: Patients treated with Lenalidomide face a significantly increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke. Prophylactic antithrombotic therapy is highly recommended for most patients.

Description Lenmid 10mg Capsule: Advanced Immunomodulatory Therapy for Multiple Myeloma and Myelodysplastic Syndromes Extensive Product Profile: In-Depth Insights on Lenmid 10mg Capsules Lenmid 10mg Capsule, manufactured under strict global compliance systems within India by Cipla Ltd. (Oncology Division), is a highly effective, mid-range oral antineoplastic and immunomodulatory treatment. Each capsule contains precisely Lenalidomide ($10text{ mg}$) as its active pharmaceutical ingredient. Lenalidomide is a potent analogue of thalidomide belonging to the chemical class of isoindolones. It is designed to selectively manipulate cellular environments, alter cytokine release, and stimulate defense cells to disrupt blood-based cancers at their core. 1. Clinical Indications & Target Therapeutic Applications Multiple Myeloma (MM): Used in combination with dexamethasone or as a standalone maintenance therapy following autologous stem cell transplantation (ASCT) for patients with newly diagnosed or relapsed/refractory multiple myeloma. The $10text{ mg}$ strength is highly utilized for strategic dose maintenance or during scheduled step-down titration cycles to control drug toxicity. Multiple Myeloma (MM): Used in combination with dexamethasone or as a standalone maintenance therapy following autologous stem cell transplantation (ASCT) for patients with newly diagnosed or relapsed/refractory multiple myeloma. The $10text{ mg}$ strength is highly utilized for strategic dose maintenance or during scheduled step-down titration cycles to control drug toxicity. Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which must have included bortezomib. 2. Comprehensive Mechanism of Action (MOA) Cereblon E3 Ubiquitin Ligase Binding: Lenalidomide binds directly to cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex. This binding selectively alters the substrate specificity of the ligase, targeting two essential lymphoid transcription factors—IKZF1 (Ikaros) and IKZF3 (Aiolos)—for rapid cellular degradation. Direct Tumor Suppression & Apoptosis: The destruction of Ikaros and Aiolos causes a down-regulation of crucial survival factors in B-cell malignancies, leading to immediate cell cycle arrest and programmed cell death (apoptosis) in malignant plasma cells. 3. Storage, Stability, and Handling Protocols Environmental Matrix: Store Lenmid 10mg Capsules in their original moisture-resistant container or blister packaging at controlled room temperature, strictly below 30°C (86°F). Protect the inventory from high ambient steam, humidity, heat, and direct exposure to light. Administration Matrix: Capsules must be swallowed completely whole with a glass of water, once daily at the same time, either with or without food. Do not crush, chew, open, or break the capsule shell, as direct contact with the internal powder poses handling risks and alters designated absorption rates.

Description Sutykine 25mg Capsule: Advanced Multi-Targeted Receptor Tyrosine Kinase Inhibitor for Advanced Oncology Supply Chains Extensive Product Profile: In-Depth Insights on Sutykine 25mg Capsules Sutykine 25mg Capsule, manufactured under strict global compliance systems within India by Intas Pharmaceuticals Ltd., is a breakthrough oral targeted antineoplastic therapy. Each hard gelatin capsule contains precisely Sunitinib Malate equivalent to Sunitinib ($25text{ mg}$) as its active pharmaceutical ingredient. Sunitinib is a small-molecule, multi-targeted tyrosine kinase inhibitor (TKI) that simultaneously disrupts tumor cell proliferation and tumor angiogenesis (the formation of new blood vessels), making it a cornerstone therapy in modern oncology. 1. Clinical Indications & Target Therapeutic Applications Metastatic Renal Cell Carcinoma (mRCC): Indicated for the first-line treatment of advanced or metastatic kidney cancer, and as an adjuvant therapy to prevent recurrence in patients at high risk following a nephrectomy (kidney removal surgery). Gastrointestinal Stromal Tumors (GIST): Prescribed for patients with unresectable or metastatic gastrointestinal stromal tumors (rare cancers of the stomach, bowel, or esophagus), particularly following disease progression or structural intolerance to frontline imatinib mesylate therapy. 2. Comprehensive Mechanism of Action (MOA) Multi-Receptor Blockade: Sunitinib selectively binds to and inhibits multiple receptor tyrosine kinases (RTKs) involved in tumor growth, pathologic angiogenesis, and metastatic progression. It blocks VEGFR-1, VEGFR-2, and VEGFR-3 (Vascular Endothelial Growth Factor Receptors) alongside PDGFR-$alpha$ and PDGFR-$beta$ (Platelet-Derived Growth Factor Receptors). Anti-Angiogenesis Effect: By systematically shutting down VEGFR and PDGFR, Sutykine prevents endothelial cells from forming new blood vessels. This effectively cuts off the tumor’s baseline oxygen and nutrient supply, putting a halt to its life support system. 3. Storage, Stability, and Handling Protocols Environmental Matrix: Store Sutykine 25mg Capsules in their original moisture-resistant packaging at controlled room temperature, strictly below 30°C (86°F). Protect the inventory from high ambient steam, humidity, heat, and direct exposure to light. Keep out of reach of children.

Description Extensive Product Profile: Understanding Tamorel (Tamoxifen Citrate 20 mg) Tamorel, containing 20 mg of tamoxifen citrate, is a non-steroidal selective estrogen receptor modulator (SERM). It is widely utilized in oncology for its ability to selectively bind to estrogen receptors, acting as an antagonist in breast tissue while exhibiting estrogenic agonist effects in other parts of the body, such as the bones and uterus. 1. Clinical Indications & Usage Breast Cancer Treatment: It is indicated for the treatment of metastatic breast cancer and as adjuvant therapy for node-positive or node-negative breast cancer following surgery and radiation. Breast Cancer Prevention: Used for the primary prevention of invasive breast cancer in women at moderate or high risk, and to reduce the risk of invasive breast cancer in women with Ductal Carcinoma in Situ (DCIS). Anovulatory Infertility: Utilized to induce ovulation in women with anovulatory cycles. Other Conditions: Occasionally used off-label for conditions such as McCune-Albright syndrome, gynecomastia, and certain metastatic cancers. 2. Mechanism of Action Estrogen Receptor Modulation: It competes with estrogen for binding sites on estrogen receptors. Antitumor Effect: In breast tissue, it exerts anti-estrogenic activity, blocking the signals required for the growth and multiplication of hormone receptor-positive cancer cells. Tissue-Specific Agonism: In other tissues like bone, it acts as an estrogen agonist, helping to maintain bone mineral density and potentially reducing the risk of osteoporosis in postmenopausal women. 3. Administration and Dosing Route: Tamorel 20 mg is an oral tablet formulation. Standard Schedule: The recommended daily dose for breast cancer is typically 20 mg. For infertility, dosing is specific to the menstrual cycle and may be adjusted by a physician. Consistency: Tablets should be taken at the same time each day, with or without food. ⚠️ Safety, Side Effects, and Monitoring Common Side Effects: Frequently reported effects include hot flashes, vaginal discharge, menstrual irregularities, fatigue, and mood changes. Serious Risks: There is an increased risk of thromboembolic events (DVT, pulmonary embolism, stroke) and uterine malignancies, including endometrial cancer. Monitoring: Periodic blood counts, liver function tests, and gynecological examinations are recommended. Patients should immediately report any unusual vaginal bleeding, pelvic pain, or respiratory distress.

Description Knowledge About Abiraterone Acetate Tablets USP 250 mg Abiraterone Acetate Tablets USP 250 mg is a prescription androgen biosynthesis inhibitor used in the treatment of advanced prostate cancer. It works by reducing the body's production of testosterone and other androgens that stimulate prostate cancer growth. The medicine is generally prescribed together with corticosteroid therapy, according to the oncologist's treatment plan. Composition Component Details Product Name Abiraterone Acetate Tablets USP Generic Name Abiraterone Acetate Strength 250 mg Dosage Form Film-Coated Tablet Drug Class Androgen Biosynthesis Inhibitor Route of Administration Oral Therapeutic Category Oncology / Prostate Cancer Prescription Status Prescription Only Why Is the Correct Dosage Important? Abiraterone therapy requires careful dose management to achieve the best treatment outcome while minimizing adverse effects. Healthcare providers determine treatment after considering: Stage of prostate cancer Liver function Blood pressure Potassium levels Overall medical condition Concurrent medications Response to previous therapy Patients should take the medicine exactly as prescribed and should not change the dose without consulting their oncologist. Important Precautions Before starting Abiraterone treatment, patients should inform their healthcare provider if they have: Liver disease High blood pressure Heart disease Low potassium levels Diabetes Kidney disorders History of adrenal gland disorders Any ongoing prescription medicines or herbal supplements Available Strengths Abiraterone Acetate Tablets USP 250 mg Abiraterone Acetate Tablets 500 mg Frequently Asked Questions 1. How should Abiraterone Acetate Tablets USP 250 mg be taken? Abiraterone tablets should be taken orally as directed by a healthcare professional, usually on an empty stomach. Patients must follow the prescribed schedule strictly for optimal results. 2. Are there any dietary restrictions while taking Abiraterone? Yes, Abiraterone should be taken on an empty stomach, as food can significantly increase the absorption of the drug and may lead to unwanted side effects. 3. How long does Abiraterone treatment typically last? The duration of treatment depends on the patient's condition and response to therapy. It is usually continued as long as the patient is benefiting and tolerating the medication well. 4. Is regular monitoring required during treatment? Yes, patients undergoing Abiraterone therapy require regular monitoring of liver function, blood pressure, and potassium levels to ensure safety and effectiveness. 5. Can Abiraterone be used in combination with other cancer treatments? Abiraterone is often used in combination with corticosteroids and may be part of a broader treatment plan that includes other therapies, depending on the oncologist’s recommendation.

Description Benefits of Altretamine Capsules 50 mg Altretamine Capsules 50 mg is an oral anticancer medicine primarily used in specific ovarian cancer treatment protocols. It offers a convenient oral dosage form and may be prescribed when other treatment options are no longer effective or are considered unsuitable by the treating oncologist. Key Benefits Oral chemotherapy capsule for convenient administration. Used in selected ovarian cancer treatment plans. May help slow the growth of cancer cells. Suitable for long-term treatment under specialist supervision. Frequently supplied to oncology hospitals and cancer centers. Available for international pharmaceutical procurement and wholesale supply. Medical Uses Healthcare professionals may prescribe Altretamine capsules for the following: Persistent ovarian cancer Recurrent ovarian cancer Advanced epithelial ovarian carcinoma Selected oncology treatment protocols determined by the treating physician The medicine should always be used according to the oncologist's recommendations. How Does Altretamine Work? Altretamine belongs to the antineoplastic (anticancer) class of medicines. After administration, it is converted into active compounds that interfere with the DNA of rapidly dividing cancer cells. This process slows abnormal cell growth and helps reduce tumor progression. Frequently Asked Questions For what conditions are Altretamine Capsules 50 mg prescribed? Altretamine is typically recommended by oncologists for patients dealing with persistent or recurring ovarian cancer as part of a specialized treatment plan. Is altretamine taken as an oral chemotherapy treatment? Yes, Altretamine is available in capsule form and is taken orally. It should always be used strictly according to the instructions provided by a qualified oncologist. Who can purchase or import Altretamine internationally? Authorized entities such as hospitals, licensed pharmaceutical distributors, oncology centers, wholesalers, and government agencies can procure Altretamine through approved exporters, in compliance with local regulations. What dosage strength is available for Altretamine capsules? Altretamine is commonly supplied in a 50 mg capsule strength for clinical use. Is a bulk supply of Altretamine capsules possible? Yes, bulk orders can be arranged for licensed pharmaceutical buyers, depending on availability and adherence to the import laws of the destination country.